Alpha Teknova, Inc. (TKNO)

Market Cap	278.41M
Revenue (ttm)	37.75M
Net Income (ttm)	-26.75M
Shares Out	53.44M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	412,060
Open	5.36
Previous Close	5.44
Day's Range	5.06 - 5.47
52-Week Range	1.16 - 10.37
Beta	0.42
Analysts	Buy
Price Target	5.00 (-4.03%)
Earnings Date	Mar 4, 2025

About TKNO

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 173
• Stock Exchange: NASDAQ
• Ticker Symbol: TKNO
• Website: https://www.teknova.com

Financial Performance

In 2024, Alpha Teknova's revenue was $37.75 million, an increase of 2.89% compared to the previous year's $36.68 million. Losses were -$26.75 million, -27.28% less than in 2023.

Analyst Forecast

According to one analyst, the rating for TKNO stock is "Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(-4.03% downside)

Analyst Consensus: Buy